GSA Capital Partners LLP Sells 55,000 Shares of Luminex Corporation (LMNX)
GSA Capital Partners LLP decreased its holdings in shares of Luminex Corporation (NASDAQ:LMNX) by 21.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 197,002 shares of the medical instruments supplier’s stock after selling 55,000 shares during the quarter. Luminex Corporation comprises about 0.3% of GSA Capital Partners LLP’s investment portfolio, making the stock its 20th largest position. GSA Capital Partners LLP owned about 0.45% of Luminex Corporation worth $4,161,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE raised its stake in Luminex Corporation by 9.9% during the first quarter. Bank of America Corp DE now owns 322,154 shares of the medical instruments supplier’s stock valued at $5,917,000 after purchasing an additional 29,107 shares in the last quarter. State Street Corp raised its stake in Luminex Corporation by 13.0% during the first quarter. State Street Corp now owns 1,009,789 shares of the medical instruments supplier’s stock valued at $18,548,000 after purchasing an additional 116,351 shares in the last quarter. BlackRock Inc. raised its stake in Luminex Corporation by 52,547.0% during the first quarter. BlackRock Inc. now owns 5,063,064 shares of the medical instruments supplier’s stock valued at $93,008,000 after purchasing an additional 5,053,447 shares in the last quarter. Karp Capital Management Corp purchased a new stake in Luminex Corporation during the first quarter valued at $225,000. Finally, Marshall Wace North America L.P. raised its stake in Luminex Corporation by 6.8% during the second quarter. Marshall Wace North America L.P. now owns 88,236 shares of the medical instruments supplier’s stock valued at $1,853,000 after purchasing an additional 5,584 shares in the last quarter. 77.95% of the stock is currently owned by institutional investors.
A number of research firms recently issued reports on LMNX. ValuEngine raised shares of Luminex Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Zacks Investment Research raised shares of Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Monday, July 17th. BidaskClub downgraded shares of Luminex Corporation from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. TheStreet downgraded shares of Luminex Corporation from a “b” rating to a “c+” rating in a research note on Monday, August 7th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $21.00 price target on shares of Luminex Corporation in a research note on Friday, June 9th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $21.40.
In other news, Director Robert J. Cresci sold 19,631 shares of Luminex Corporation stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total transaction of $372,596.38. Following the transaction, the director now owns 260,358 shares in the company, valued at approximately $4,941,594.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is owned by insiders.
Luminex Corporation (NASDAQ:LMNX) traded down 0.71% on Tuesday, reaching $19.67. 37,536 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $19.46 and a 200 day moving average price of $19.69. Luminex Corporation has a one year low of $17.64 and a one year high of $23.62. The firm has a market cap of $866.88 million, a PE ratio of 60.90 and a beta of 0.27.
Luminex Corporation (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.20 EPS for the quarter, topping the consensus estimate of $0.09 by $0.11. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The business had revenue of $76.50 million for the quarter, compared to analyst estimates of $75.45 million. During the same quarter in the previous year, the firm earned $0.33 EPS. The company’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, equities analysts anticipate that Luminex Corporation will post $0.53 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 22nd will be issued a dividend of $0.06 per share. The ex-dividend date is Thursday, September 21st. This represents a $0.24 annualized dividend and a dividend yield of 1.21%. Luminex Corporation’s dividend payout ratio is presently 75.00%.
TRADEMARK VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/19/gsa-capital-partners-llp-sells-55000-shares-of-luminex-corporation-lmnx.html.
Luminex Corporation Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Corporation (NASDAQ:LMNX).
Receive News & Stock Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related stocks with our FREE daily email newsletter.